This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

MVP - Medical Developments International

Jump to new
Thanks rcm617.
I was a bit surprised that the surge was so large.
 


MVP looks set for a BO-HR after a Close at $17.34. With a current average spread of around 20¢ a BO could be imminent.
The ATH is sitting at $8.07.
 
I took some profits, sold a third at $6.70, got my capital back, but the strength is amazing.
I am struggling to see value at this price. Missing something.
 
Thrown this one in as my top pick in the yearly comp. Don't know a lot about them but they seem confident of further deals/growth.

The chart looks toppy but where healthcare is involved things can be unpredictable, and it has a year to gyrate

 
I own this, good company. Was going to pick but taken off. Could keep going especially if USA approval received during year.
 
Knobby22 said:
I own this, good company. Was going to pick but taken off. Could keep going especially if USA approval received during year.
Click to expand...
Ive been watching them, since reading about them on ASF, waiting for an entry opportunity if one presents.
Hopefully Trump causes a hickup in Jan/Feb, before the run up to the election.
 
As mentioned, my top pick for the yearly comp ….

Could have waited a couple of days before the breakout

Its getting a bit exponential but with a year to run it might creep a bit higher.

Could be your shout @Knobby22 if it keeps going

 
A friend of mine did some "in the field" checking with an emergency department physician he knows.

The feedback was
"Administration of intranasal fentanyl is vastly more effective, odourless and safer.
Penthrox has been largely banned by ambulance services in Australia as the volatile methoxyflurane stinks, gives you a headache, evaporates all around the back of the ambulance (NSW Ambulances had to put in roof ventilation hatches to allow purging of the air if you have a patient on one.... which water pours through in the rain.

They never use them in hospitals and they are really only found in the hands of first aiders.

The company probably makes a bit of money out of them but I would not expect the market to expand. They were widely adopted in 2015 or so when they were introduced (it may have been earlier than that) and just as quickly abandoned!"

I hold MVP and was viewing it as a long term hold. When I re-examined the announcements by the company there was no mention of the above issues. I now treat it as a trading stock because the implied addressable market is not there to justify a P/E of 338X.
 
But isn't Fentanyl an opioid? I thought the whole point was to get away from those nasties.

Used to own, but MVP is a one trick pony.
 
Dona Ferentes said:
But isn't Fentanyl an opioid? I thought the whole point was to get away from those nasties.

Used to own, but MVP is a one trick pony.
Click to expand...
I am just passing on comments from a person on the ground. Sometimes this can be very inciteful.
The take-away messages I picked up from this source on about Penthrox were;
The medical profession often prefer not to use it because other drugs are more effective in most cases.
There are some serious OHS issues that need to be managed when Penthrox is used, particularly in confined spaces.
The main users will be first-aiders.
The addressable market will be significantly less than implied by the company management.

It would be particularly helpful if these issues were put to the management at the AGM and for them to explain why the above is incorrect. It won't be me because I doubt very much if it will atill be in my portfolio when the AGM comes around​
 
Sold out today at $9.21, almost a 4 bagger. Just looking too pricy for me though could easily go higher especially if USA deal occurs, good luck to holders.
 
Knobby22 said:
Sold out today at $9.21, almost a 4 bagger. Just looking too pricy for me though could easily go higher especially if USA deal occurs, good luck to holders.
Click to expand...
Getting to pricey for me. Got out after holding for 6 years. Will buy back if it drops back as I still think there is substantial growth left in this stock with penthrox and also with the CSIRO collaboration, but I think the price has shot up to quickly and earnings growth will be over a longer period of time.
 
raising $30 million at $6.50; $25mill placement + $5mill SPP


Gordon Naylor, the incoming chairman of Medical Developments International, says there are parallels with his former employer, biotech giant CSL. Mr Naylor joined MVP as a director in October. It was his first role since retiring from CSL in 2019, where he worked for more than three decades helping to take it from a small organisation to one of Australia's largest companies with global reach. He was CSL's CFO and headed up its Seqirus vaccine business, where in three years he steered it from losing $200 million to making $280 million profit.
talking his book to an extent, IMHO
 
Speaking to The Australian Financial Review on the eve of taking on his new role as chairman of pharmaceutical company Medical Developments International, Gordon Naylor says that while employees don’t need to read a company’s financial accounts, they should be well informed about basic concepts such as cashflow and profitability and be across a business’ position.

Naylor intends to bring such a transparent approach to finances to Medical Developments, which also has a new CEO in Brent MacGregor, who reported to Naylor in his time at CSL.

The pair have the task of accelerating the international commercialisation of Penthrox – a fast-acting emergency pain relief product used widely via “the green whistle” in Australia – and making the business more profitable. The company also makes a range of respiratory devices for asthma sufferers.

In the year to June 30, the company reported a 10.6 per cent jump in revenue to $23.6 million, but its net profit fell 63 per cent to $379,000. Thanks to COVID-19, Penthrox revenue declined substantially in the second half of the year as sporting events stopped and the movement of people declined.....

The $30mill placement + SPP will support its international growth and European clinical trials,
 
$5.00 to $1.40 in June and a bit of a retrace to $2.40 recently.... and now a trading Halt and Cap Raise.

Still running with Penthrox (Green Whistle) and Repiratory (Asthma).
Sales increasing, still EBIT negative.

Raising $30 million at $2.00 a share
• A fully underwritten capital raising of approximately $30 million comprising:
• An institutional placement of New Shares to eligible investors to raise approximately $15.0 million
• A 1 for 9.5 pro-rata accelerated non-renounceable entitlement issue for approx $15 million

Going towards
  • Operating activities, including growth in Europe and Australia and enhanced organisational capability
  • Capex operations
 
Gee, I thought they would be profitable by now.
 
Australia sits at no 3 on the world table for antidepressants behind iceland and the USA.
Can understand why US is at the top, and Iceland spend a lot of the time cold and in the dark, but what the hell is going on in Australia that we get prescribed so many Antidepressants?
I asked my my wife the Pharmacist, but she was wary of seeking to blame anyone.
perhaps we need an RC?
Mick
 
You must log in or register to reply here.

Similar threads

AEAE - Australian Ethical High Conviction Fund ETF
Replies
2
Views
2K
Garpal Gumnut
IPD - ImpediMed Limited
Replies
15
Views
9K
Dona Ferentes
The Beginner Trader's Manual Guide
Replies
9
Views
20K
commoyo
AJJ - Asian American Medical Group
Replies
16
Views
8K
McLovin
AVH - AVITA Medical, Inc
3 4 5
Replies
86
Views
27K
Dona Ferentes
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...